Výsledky vyhledávání

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

Autor: Alvin F. Wells, Christine Xu, Hubert van Hoogstraten, Yong Lin, Janie Parrino, Chunpeng Fan, Neil M.H. Graham, Albert Torri, E.K. Mangan, Anne Paccaly

Publikováno v: Rheumatology and Therapy
Rheumatology and Therapy, Vol 6, Iss 3, Pp 339-352 (2019)

Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional syntheti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c3df73840600d797e43ed00c8e10e8
https://doi.org/10.1007/s40744-019-0157-3

Zobrazit plný text záznamu

Plný text ve formátu HTML

Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale

Autor: Toshio Kimura, Hubert van Hoogstraten, Sophie Guillonneau, Laure Gossec, Chieh-I Chen, E.K. Mangan, Clare Proudfoot, M. Reaney, Vibeke Strand

Publikováno v: Journal of Rheumatology
Journal of Rheumatology, Journal of Rheumatology Publishing Company Limited, 2019, 46 (10), pp.1259-1267. ⟨10.3899/jrheum.180904⟩

Objective.We evaluated the effect of sarilumab on patient-perceived impact of rheumatoid arthritis (RA) using the 7-domain RA Impact of Disease (RAID) scale.Methods.Two phase III, randomized, controlled trials of sarilumab in patients with active, lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::330fc837a54bc2312048edad1b48036f
https://doi.org/10.3899/jrheum.180904

Zobrazit plný text záznamu

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs

Autor: E.K. Mangan, Clare Proudfoot, Nick Freemantle, Hubert van Hoogstraten, Chieh-I Chen, Thi-Minh-Thao Huynh, Andreas Kuznik, Ernest Choy, Paulo Carita, Laurence Pollissard

Publikováno v: Advances in Therapy

Introduction To evaluate the comparative efficacy and safety of subcutaneous sarilumab 200 mg monotherapy administered every 2 weeks (q2w) versus other monotherapies of biologic, targeted and conventional synthetic disease-modifying antirheumatic dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ab92c2de38529d7b53f09313a2784ab
http://europepmc.org/articles/PMC6824353

Zobrazit plný text záznamu

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial

Autor: Paul Emery, Karthinathan Thangavelu, Hubert van Hoogstraten, Patrick Verschueren, Gregory St John, E.K. Mangan

Publikováno v: ACR Open Rheumatology, Vol 2, Iss 11, Pp 672-680 (2020)
ACR Open Rheumatology

OBJECTIVE: This post hoc analysis evaluated the safety and efficacy of open-label sarilumab in patients with rheumatoid arthritis (RA) who completed the phase III double-blind ASCERTAIN study (NCT01768572) and switched from intravenous (IV) tocilizum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fed3363a8cc16fa0c317a0be8a370d3
https://lirias.kuleuven.be/handle/123456789/663554

Zobrazit plný text záznamu

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies

Autor: Roy Fleischmann, Eun-Bong Lee, Hubert van Hoogstraten, Mark C. Genovese, Alan Kivitz, Gerd R Burmester, Gregory St John, Toshio Kimura, E.K. Mangan

Publikováno v: Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-17 (2020)

Background The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely active rheumatoid ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ad974c9ef0426e024f16985078c382
https://doi.org/10.1186/s13075-020-02194-z

Zobrazit plný text záznamu

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes

Autor: Janie Parrino, Hubert van Hoogstraten, Extend study investigators, Neil M.H. Graham, Janet van Adelsberg, Chunpeng Fan, Alberto Spindler, Tom W J Huizinga, E.K. Mangan, Désirée van der Heijde, Mark C. Genovese

Publikováno v: Rheumatology (Oxford, England)

Objectives To examine 2-year safety, efficacy and radiographic outcomes of sarilumab in adults with RA and inadequate response to MTX (MTX-IR). Methods In the randomized, placebo-controlled MOBILITY trial, MTX-IR patients received subcutaneous sarilu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e53709963e197fb428d7763401ae127
http://europepmc.org/articles/PMC6055572

Zobrazit plný text záznamu

Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders

Autor: Johnathan A. Khusid, Martin Carlsson, E.K. Mangan, Jeffrey P. Weiss

Publikováno v: Journal of Urology. 198:1119-1123

A recent study demonstrated improvement in nocturnal urgency in patients with overactive bladder when treated with fesoterodine. In the current study we aimed to determine which bladder diary parameters predict the response to fesoterodine in these p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae600613bb8d462d2103780a76582243
https://doi.org/10.1016/j.juro.2017.04.098

Zobrazit plný text záznamu

SAT0121 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES

Autor: Owen Hagino, Mark C. Genovese, Thomas Mandrup-Poulsen, E.K. Mangan, Karthinathan Thangavelu, Gerd R Burmester, Hubert van Hoogstraten, Roy Fleischmann

Publikováno v: SATURDAY, 15 JUNE 2019.

Background Sarilumab is a human mAb blocking the IL-6Rα, approved for adult patients with moderately to severely active RA. The incidence of Type 2 diabetes is increased in patients with RA, and elevated IL-6 may be an independent risk factor. Objec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee7d0a652c4ad912ec0dd7c9f4119b0f
https://doi.org/10.1136/annrheumdis-2019-eular.3259

Zobrazit plný text záznamu

THU0215 Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab

Autor: E.K. Mangan, A.A. den Broeder, H. van Hoogstraten, Patrick Verschueren, Paul Emery, Q. Dong

Publikováno v: THURSDAY, 14 JUNE 2018.

Background Sarilumab is an IL-6R inhibitor recently approved for the treatment of rheumatoid arthritis (RA). To help clinical decision making, we studied the response rate on open-label sarilumab treatment in patients previously treated with tocilizu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2981b983eaca1734aa7763694dc024d
https://doi.org/10.1136/annrheumdis-2018-eular.1376

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání